|Symbols||; AEMK; EA1; HBK1; HUK1; KV1.1; MBK1; MK1; RBK1|
|External IDs||IUPHAR: ChEMBL: GeneCards:|
Potassium voltage-gated channel subfamily A member 1 also known as Kv1.1 is a shaker related voltage-gated potassium channel that in humans is encoded by the KCNA1 gene. The Isaacs syndrome is a result of an autoimmune reaction against the Kv1.1 ion channel.
The gene is located on the Watson (plus) strand of the short arm of chromosome 12 (12p13.32). The gene itself is 8,348 bases in length and encodes a protein of 495 amino acids (predicted molecular weight 56.466 kiloDaltons).
The recommended name for this protein is potassium voltage-gated channel subfamily A member 1 but a number of alternatives have been used in the literature including HuK1 (human K+ channel I), RBK1 (rubidium potassium channel 1), MBK (mouse brain K+ channel), voltage gated potassium channel HBK1, voltage gated potassium channel subunit Kv1.1, voltage-gated K+ channel HuKI and AEMK (associated with myokymia with periodic ataxia).
The protein is believed to have six domains (S1-S6) with the loop between S5 and S6 forming the channel pore. This region also has a conserved selectivity filter motif. The functional channel is a homotetramer. The N-terminus of the protein associates with β subunits. These subunits regulate channel inactivation as well as its expression. The C-terminus is associated with a PDZ domain protein involved in channel targeting.
The protein functions as a potassium selective channel through which the potassium ion may pass in consensus with the electrochemical gradient. They play a role in repolarisation of membranes.
A to I RNA editing is catalyzed by a family of adenosine deaminases acting on RNA (ADARs) that specifically recognize adenosines within double-stranded regions of pre-mRNAs (e.g. Potassium channel RNA editing signal) and deaminate them to inosine. Inosines are recognised as guanosine by the cells translational machinery. There are three members of the ADAR family ADARs 1-3 with ADAR1 and ADAR2 being the only enzymatically active members. ADAR3 is thought to have a regulatory role in the brain. ADAR1 and ADAR2 are widely expressed in tissues while ADAR3 is restricted to the brain. The double stranded regions of RNA are formed by base-pairing between residues in the region close to the editing site with residues usually in a neighboring intron but can sometimes be an exonic sequence too. The region that base pairs with the editing region is known as an Editing Complementary Sequence (ECS).
The modified residue is found at amino acid 400 of the final protein. This is located in the sixth transmembrane region found, which corresponds to the inner vestibule of the pore. A stem loop hairpin structure mediates the RNA editing. ADAR2 is likely to be the preferred editing enzyme at the I/V site. Editing results in a codon alteration from ATT to GTT, resulting in an amino acid change from isoleucine to valine. ADAR2 enzyme is the major editing enzyme. The MFOLD programme predicted that the minimum region required for editing would form an imperfect inverted repeat hairpin. This region is composed of a 114 base pairs. Similar regions have been identified in mouse and rat. The edited adenosine is found in a 6-base pair duplex region. Mutation experiment in the region near the 6-base pair duplex have shown that the specific bases in this region were also essential for editing to occur. The region required for editing is unusual in that the hairpin structure is formed by exonic sequences only. In the majority of A to I editing the ECS is found within an intronic sequence.
The editing is highly conserved having been observed in squid, fruit fly, mouse, and rat.
Editing results in a codon (I/V) change from (ATT) to (GTT) resulting in translation of a valine instead of an isoleucine at the position of the editing site. Valine has a larger side-chain. RNA editing at this position occurs at a highly conserved ion conducting pore of the channel. This may affect the channels role in the process of fast inactivation.
Voltage-dependent potassium channels modulate excitability by opening and closing a potassium selective pore in response to voltage. The flow of potassium ions is interrupted by interaction of an inactivating particle, an auxiliary protein in humans but an intrinsic part of the channel in other species. The I to V amino acid change is thought to disrupt the hydrophobic interaction between the inactivating particle and the pore lining. This interrupts the process of fast inactivation. Activation kinetics are unaffected by RNA editing. Changes in inactivation kinetics have an impact on the duration and frequency of the action potential. An edited channel passes more current and has a shorter action potential than the non-edited type due to the inability of the inactivating particle to interact with the residue in the ion-conducting pore of the channel.This was determined by electrophysiology analysis. The length of time the membrane is depolarised is decreased, which also reduces the efficiency of transmitter release. Since editing can cause amino acid changes in 1- 4 in potassium channel tetramers, it can have a wide variety of effects on channel inactivation.
Changes in the process of fast inactivation are known to have behavioral and neurological consequences in vivo.
- GABRA3 - a channel subunit which undergoes similar RNA editing
- Curran ME, Landes GM, Keating MT (1992). "Molecular cloning, characterization, and genomic localization of a human potassium channel gene". Genomics 12 (4): 729–37. PMID 1349297. doi:10.1016/0888-7543(92)90302-9.
- Albrecht B, Weber K, Pongs O (1995). "Characterization of a voltage-activated K-channel gene cluster on human chromosome 12p13". Recept. Channels 3 (3): 213–20. PMID 8821794.
- Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stühmer W, Wang X (2005). "International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels". Pharmacol. Rev. 57 (4): 473–508. PMID 16382104. doi:10.1124/pr.57.4.10.
- Newsom-Davis J (1997). "Autoimmune neuromyotonia (Isaacs' syndrome): an antibody-mediated potassium channelopathy". Ann. N. Y. Acad. Sci. 835 (1): 111–9. Bibcode:1997NYASA.835..111N. PMID 9616766. doi:10.1111/j.1749-6632.1997.tb48622.x.
- "Entrez Gene: KCNA1 potassium voltage-gated channel".
- Bhalla T, Rosenthal JJ, Holmgren M, Reenan R (October 2004). "Control of human potassium channel inactivation by editing of a small mRNA hairpin". Nat. Struct. Mol. Biol. 11 (10): 950–6. PMID 15361858. doi:10.1038/nsmb825.
- Hoopengardner B, Bhalla T, Staber C, Reenan R (August 2003). "Nervous system targets of RNA editing identified by comparative genomics". Science 301 (5634): 832–6. Bibcode:2003Sci...301..832H. PMID 12907802. doi:10.1126/science.1086763.
- Bhalla, Tarun (2004). "Control of human potassium channel inactivation by editing of a small mRNA hairpin". Nature Structural 11 (10): 950–956. PMID 15361858. doi:10.1038/nsmb825.
- Grunnet M, Rasmussen HB, Hay-Schmidt A et al. (2003). "KCNE4 is an inhibitory subunit to Kv1.1 and Kv1.3 potassium channels.". Biophys. J. 85 (3): 1525–37. Bibcode:2003BpJ....85.1525G. PMC 1303329. PMID 12944270. doi:10.1016/S0006-3495(03)74585-8.
- Nie DY, Zhou ZH, Ang BT et al. (2003). "Nogo-A at CNS paranodes is a ligand of Caspr: possible regulation of K(+) channel localization.". EMBO J. 22 (21): 5666–78. PMC 275427. PMID 14592966. doi:10.1093/emboj/cdg570.
- Imbrici P, Cusimano A, D'Adamo MC et al. (2003). "Functional characterization of an episodic ataxia type-1 mutation occurring in the S1 segment of hKv1.1 channels.". Pflugers Arch. 446 (3): 373–9. PMID 12799903. doi:10.1007/s00424-002-0962-2.
- Glaudemans B, van der Wijst J, Scola RH et al. (2009). "A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia.". J. Clin. Invest. 119 (4): 936–42. PMC 2662556. PMID 19307729. doi:10.1172/JCI36948.
- Shook SJ, Mamsa H, Jen JC et al. (2008). "Novel mutation in KCNA1 causes episodic ataxia with paroxysmal dyspnea.". Muscle Nerve 37 (3): 399–402. PMID 17912752. doi:10.1002/mus.20904.
- Gubitosi-Klug RA, Mancuso DJ, Gross RW (2005). "The human Kv1.1 channel is palmitoylated, modulating voltage sensing: Identification of a palmitoylation consensus sequence.". Proc. Natl. Acad. Sci. U.S.A. 102 (17): 5964–8. Bibcode:2005PNAS..102.5964G. PMC 1087951. PMID 15837928. doi:10.1073/pnas.0501999102.
- Zhang ZH, Rhodes KJ, Childers WE et al. (2004). "Disinactivation of N-type inactivation of voltage-gated K channels by an erbstatin analogue.". J. Biol. Chem. 279 (28): 29226–30. PMID 15136567. doi:10.1074/jbc.M403290200.
- Kimura K, Wakamatsu A, Suzuki Y et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.". Genome Res. 16 (1): 55–65. PMC 1356129. PMID 16344560. doi:10.1101/gr.4039406.
- Jow F, Zhang ZH, Kopsco DC et al. (2004). "Functional coupling of intracellular calcium and inactivation of voltage-gated Kv1.1/Kvbeta1.1 A-type K+ channels.". Proc. Natl. Acad. Sci. U.S.A. 101 (43): 15535–40. Bibcode:2004PNAS..10115535J. PMC 524431. PMID 15486093. doi:10.1073/pnas.0402081101.
- Imbrici P, Grottesi A, D'Adamo MC et al. (2009). "Contribution of the central hydrophobic residue in the PXP motif of voltage-dependent K+ channels to S6 flexibility and gating properties.". Channels (Austin) 3 (1): 39–45. PMID 19202350. doi:10.4161/chan.3.1.7548.
- Kinali M, Jungbluth H, Eunson LH et al. (2004). "Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia.". Neuromuscul. Disord. 14 (10): 689–93. PMID 15351427. doi:10.1016/j.nmd.2004.06.007.
- Demos MK, Macri V, Farrell K et al. (2009). "A novel KCNA1 mutation associated with global delay and persistent cerebellar dysfunction.". Mov. Disord. 24 (5): 778–82. PMID 19205071. doi:10.1002/mds.22467.
- Imbrici P, Gualandi F, D'Adamo MC et al. (2008). "A novel KCNA1 mutation identified in an Italian family affected by episodic ataxia type 1.". Neuroscience 157 (3): 577–87. PMID 18926884. doi:10.1016/j.neuroscience.2008.09.022.
- Tan KM, Lennon VA, Klein CJ et al. (2008). "Clinical spectrum of voltage-gated potassium channel autoimmunity.". Neurology 70 (20): 1883–90. PMID 18474843. doi:10.1212/01.wnl.0000312275.04260.a0.
- Chen H, von Hehn C, Kaczmarek LK et al. (2007). "Functional analysis of a novel potassium channel (KCNA1) mutation in hereditary myokymia.". Neurogenetics 8 (2): 131–5. PMC 1820748. PMID 17136396. doi:10.1007/s10048-006-0071-z.
- Strausberg RL, Feingold EA, Grouse LH et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. Bibcode:2002PNAS...9916899M. PMC 139241. PMID 12477932. doi:10.1073/pnas.242603899.
- Gutman GA, Chandy KG, Grissmer S et al. (2005). "International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels.". Pharmacol. Rev. 57 (4): 473–508. PMID 16382104. doi:10.1124/pr.57.4.10.
- Lee H, Wang H, Jen JC et al. (2004). "A novel mutation in KCNA1 causes episodic ataxia without myokymia.". Hum. Mutat. 24 (6): 536. PMID 15532032. doi:10.1002/humu.9295.
- Gu C, Jan YN, Jan LY (2003). "A conserved domain in axonal targeting of Kv1 (Shaker) voltage-gated potassium channels.". Science 301 (5633): 646–9. Bibcode:2003Sci...301..646G. PMID 12893943. doi:10.1126/science.1086998.
- GeneReviews/NCBI/NIH/UW entry on Episodic Ataxia Type 1,Episodic Ataxia with Myokymia, Hereditary Cerebellar Ataxia with Neuromyotonia
- Kv1.1 Potassium Channel at the US National Library of Medicine Medical Subject Headings (MeSH)
- KCNA1 protein, human at the US National Library of Medicine Medical Subject Headings (MeSH)